Addressing Evolving Educational Needs on BTK Inhibitor Therapies in CLL/SLL and MCL

Join us for this dynamic, case-based, 1-hour CME-certified live webinar, in which an expert panel will discuss key areas of consensus and controversy involving existing and emerging BTK inhibitors therapies in CLL/SLL and MCL in a virtual talk-show format. Sign up today!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Overview of BTK Inhibitors for CLL/SLL and MCL
    • MOA and specificity of available and emerging agents, with a focus on impact on efficacy and safety
  • Selecting the Most Appropriate Therapy/Sequence of Therapies in R/R MCL and CLL/SLL
    • Case series
    • Key efficacy and safety data
    • Overcoming resistance
    • Novel approaches
  • Audience Q&A


Date / Time
Event Details


Program Director
Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Target Audience
This educational program is intended for hematologist-oncologists and other healthcare professionals who care for patients with MCL and CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Understand the current knowledge, competence, and performance gaps that exist among healthcare professionals on the current BTK inhibitor treatment landscape for R/R MCL and CLL/SLL
  • Identify potential barriers to selecting the most appropriate therapies (including sequence of therapies) for patients with for R/R MCL and CLL/SLL
  • Evaluate differences between BTK inhibitors in terms of molecular characteristics, selectivity, binding properties, dosing, safety profile, and efficacy
  • Recommend single-agent, sequential, or combination strategies using BTK inhibitors in R/R MCL and CLL/SLL utilizing updated clinical evidence, expert guidance, and practice guideline recommendations
  • Manage the unique spectrum of toxicity associated with the use of current and emerging BTK inhibitors
  • Identify patients eligible for enrollment on ongoing clinical trials investigating available and emerging BTK inhibitors as single agents and in combination for R/R MCL and CLL/SLL


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.